Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
UPS cuts outlook, Moody's downgrades U.S. banks, Eli Lilly raises guidance: Aug 8, 2023
11:04am, Tuesday, 08'th Aug 2023
Yahoo Finance anchor Julie Hyman breaks down three things to know for August 8, 2023 including UPS earnings, Moody's downgrading U.S. banks, and Eli Lilly raising guidance.
Call Traders Blast Ely Lilly Stock Amid Post-Earnings Peak
10:15am, Tuesday, 08'th Aug 2023
The shares of Eli Lilly And Co (NYSE:LLY) are trading at record highs today, last seen up 16% at $522.45, following a blockbuster trip to the earnings confessional.
Eli Lilly (LLY) Q2 Earnings and Revenues Top Estimates
09:10am, Tuesday, 08'th Aug 2023
Eli Lilly (LLY) came out with quarterly earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.25 per share a year ago.
Wegovy's success in reducing cardio risk is ‘an important win,' and a ‘best-case scenario,' say Wolfe analysts
08:02am, Tuesday, 08'th Aug 2023
The success of Novo Nordisk's NVO, +3.04% NOVO.B, +13.49% Wegovy in reducing cardiovascular events in obese adults is an important win for the obesity category with positive implications for that comp
Dow seen lower as Moody's hits banks but Eli Lilly set to fly
07:56am, Tuesday, 08'th Aug 2023
7.50am: Banks hit by Moody's downgrades, Eli Lilly ups guidance US stocks are expected to open lower with banks under pressure after Moody's downgraded ratings for a number of small to mid-sized lende
Eli Lilly stock up in premarket as Mounjaro diabetes drug sales surge
07:46am, Tuesday, 08'th Aug 2023
Eli Lilly and Co (NYSE:LLY) stock is seen higher ahead of Tuesday's open after reporting a strong, expectation-beating, second-quarter performance led by type-2 diabetes drug Mounjaro. Revenue for the
Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
07:04am, Tuesday, 08'th Aug 2023
Eli Lilly's stock has been on a tear, driven by positive trial results for its Alzheimer's drug and progress with its promising obesity drug pipeline.
Eli Lilly beats profit estimates on strength of new diabetes drug
06:51am, Tuesday, 08'th Aug 2023
Eli Lilly beat Wall Street estimates for second-quarter profit on Tuesday, buoyed by strong demand for its new diabetes drugs Mounjaro, ahead of a decision on the medicine's use as a weight-loss treat
Indices Fight Back; PLTR Meets, SWKS and PARA Beat
07:39pm, Monday, 07'th Aug 2023
The Dow climbed back +408 points on the day, +1.16%, while the Nasdaq gained +84 points, +0.61%.
People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared Holz
06:42pm, Monday, 07'th Aug 2023
Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk Eli Lilly earnings, obesity drug demand and more.
Options Action: Traders bearish on Eli Lilly ahead of earnings
06:06pm, Monday, 07'th Aug 2023
Mike Khouw, Optimize Advisors president, joins CNBC's Melissa Lee and the Options Action traders to talk Eli Lilly.
Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment
11:30am, Monday, 07'th Aug 2023
Nektar Therapeutics on Monday sued Eli Lilly , accusing the drugmaker of undermining the prospects for Rezpeg, which Nektar was developing as a treatment for various autoimmune diseases.
Eli Lilly expected to deliver a solid if unspectacular earnings update
10:01am, Monday, 07'th Aug 2023
Eli Lilly and Company is slated to unveil its second-quarter 2023 results on Tuesday (August), prior to the market opening, with Wall Street expecting earnings of $1.98 a share. That's up around 9%
Nektar rallies after releasing new data for rezpeg after Eli Lilly got it wrong
08:10am, Monday, 07'th Aug 2023
Nektar Therapeutics (NASDAQ:NKTR) shares rallied more than 15% in Monday pre-market trading after the company released new efficacy data from phase 1b studies from rezpegaldesleukin (rezpeg) after th
Nektar Therapeutics' stock NKTR, +3.14% jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli Lilly & Co. LLY, +0.07% for its
